1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Work
Year: 2022
Type: article
Source: Annals of Oncology
Institutions Columbia University Irving Medical Center, Sarah Cannon, Tennessee Oncology, Duke Medical Center, AstraZeneca (United States) +1 more
Cites: 1
Cited by: 2
Related to: 10
FWCI: 0.466
Citation percentile (by year/subfield): 65.44
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze